FDA Adverse Event Injury Summary report: N

COOLSCULPTING ELITE SYSTEM

MDR report key: 15752272 · Received November 8, 2022

Report

Report Number
3007215625-2022-01679
Event Type
Injury
Date Received
November 8, 2022
Date of Event
March 28, 2022
Report Date
May 5, 2025
Manufacturer
ALLERGAN PLEASANTON
Product Code
OOK
PMA / PMN Number
K183514
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FL, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

ACCORDING TO THE COOLSCULPTING USER MANUAL, UNDER RARE ADVERSE EVENTS, PARADOXICAL ADIPOSE HYPERPLASIA (PH/PAH) IS CHARACTERIZED BY A VISIBLY ENLARGED TISSUE VOLUME WITHIN THE TREATMENT AREA, WHICH MAY DEVELOP TWO TO FIVE MONTHS AFTER TREATMENT. SURGICAL INTERVENTION MAY BE REQUIRED. PAH IS NOT RELATED TO ANY COOLSCULPTING DEVICE FAILURE MODE BUT IT IS OBSERVED MORE FREQUENTLY WITH THE PARALLEL PLATE APPLICATORS. PAH IS INCLUDED IN THE RISK MANAGEMENT FILES OF THE DEVICE AS AN INHERENT RISK TO THE USE OF CRYOLIPOLYSIS FOR LOCALIZED FAT REDUCTION. A SUPPLEMENTAL REPORT WILL BE SUBMITTED IF AND WHEN ADDITIONAL INFORMATION IS OBTAINED.

Additional Manufacturer Narrative · 0

CORRECTED DATA: A5 AND D1.

Description of Event or Problem · 0

ALLERGAN AESTHETICS RECEIVED A REPORT OF A PATIENT TREATED LOWER ABDOMEN AND UPPER BACK WITH COOLSCULPTING ELITE CURVE 120 AND CURVE 150 ON (B)(6) 2022 AND (B)(6) 2022 DEVELOPED PARADOXICAL HYPERPLASIA (PAH/PH). DIAGNOSED WITH PAH ON (B)(6) 2022 BY MEDICAL DOCTOR.

Description of Event or Problem · 0

ALLERGAN AESTHETICS RECEIVED A REPORT OF A PATIENT TREATED LOWER ABDOMEN AND UPPER BACK WITH COOLSCULPTING ELITE CURVE 120 AND CURVE 150 ON (B)(6) 2022 AND (B)(6) 2022 DEVELOPED PARADOXICAL HYPERPLASIA (PAH/PH). DIAGNOSED WITH PAH ON (B)(6) 2022 BY MEDICAL DOCTOR.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2178860 COOLSCULPTING ELITE SYSTEM DERMAL COOLING PACK/VACUUM/MASSAGER OOK ALLERGAN PLEASANTON NI

Patients

Seq Age Sex Outcome Treatment
1 50 YR Female Required Intervention